These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 32255416

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma.
    Ghai A, Maji D, Cho N, Chanswangphuwana C, Rettig M, Shen D, DiPersio J, Akers W, Dehdashti F, Achilefu S, Vij R, Shokeen M.
    J Nucl Med; 2018 Feb; 59(2):216-222. PubMed ID: 29025987
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model.
    Bailly C, Gouard S, Guérard F, Chalopin B, Carlier T, Faivre-Chauvet A, Remaud-Le Saëc P, Bourgeois M, Chouin N, Rbah-Vidal L, Tripier R, Haddad F, Kraeber-Bodéré F, Bodet-Milin C, Chérel M.
    Int J Mol Sci; 2019 May 24; 20(10):. PubMed ID: 31137758
    [Abstract] [Full Text] [Related]

  • 6. Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma.
    Ghai A, Zheleznyak A, Mixdorf M, O'Neal J, Ritchey J, Rettig M, DiPersio J, Shokeen M, Achilefu S.
    Eur J Nucl Med Mol Imaging; 2021 May 24; 48(5):1302-1311. PubMed ID: 33179150
    [Abstract] [Full Text] [Related]

  • 7. Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.
    Tendler S, Dunphy MP, Agee M, O'Donoghue J, Aly RG, Choudhury NJ, Kesner A, Kirov A, Mauguen A, Baine MK, Schoder H, Weber WA, Rekhtman N, Lyashchenko SK, Bodei L, Morris MJ, Lewis JS, Rudin CM, Poirier JT.
    Lancet Oncol; 2024 Aug 24; 25(8):1015-1024. PubMed ID: 38950555
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. CD38-Targeted Theranostics of Lymphoma with 89Zr/177Lu-Labeled Daratumumab.
    Kang L, Li C, Rosenkrans ZT, Huo N, Chen Z, Ehlerding EB, Huo Y, Ferreira CA, Barnhart TE, Engle JW, Wang R, Jiang D, Xu X, Cai W.
    Adv Sci (Weinh); 2021 May 24; 8(10):2001879. PubMed ID: 34026426
    [Abstract] [Full Text] [Related]

  • 11. Development of a Specifically Labeled 89Zr Antibody for the Noninvasive Imaging of Tumors Overexpressing B7-H3.
    Zheng M, Liu Q, Zhang H, Wang Y, Zhang K, Mu H, Fu F, Zhang X, Wang Y, Miao L.
    Mol Pharm; 2024 Oct 07; 21(10):5205-5216. PubMed ID: 39322604
    [Abstract] [Full Text] [Related]

  • 12. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing 89Zr - In vitro stability and in vivo microPET/CT imaging studies in NOD/SCID mice with HER2-positive SK-OV-3 human ovarian cancer xenografts.
    Cho H, Al-Saden N, Lam H, Möbus J, Reilly RM, Winnik MA.
    Nucl Med Biol; 2020 Oct 07; 84-85():11-19. PubMed ID: 31931305
    [Abstract] [Full Text] [Related]

  • 13. CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models.
    Kristensen LK, Fröhlich C, Christensen C, Melander MC, Poulsen TT, Galler GR, Lantto J, Horak ID, Kragh M, Nielsen CH, Kjaer A.
    Theranostics; 2019 Oct 07; 9(26):8221-8238. PubMed ID: 31754392
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. DFO-Km: A Modular Chelator as a New Chemical Tool for the Construction of Zirconium-89-Based Radiopharmaceuticals.
    Salih AK, Dominguez Garcia M, Raheem SJ, Ahiahonu WK, Price EW.
    Inorg Chem; 2023 Dec 18; 62(50):20806-20819. PubMed ID: 37751491
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Discovery of a highly specific radiolabeled antibody targeting B-cell maturation antigen: Applications in PET imaging of multiple myeloma.
    Ma J, Zhang S, Yang N, Shang J, Gao X, Chen J, Wei H, Li Y, Zeng H, Xu H, Wang J, Liang SH, Wang R, Hu K, Wang L.
    Eur J Nucl Med Mol Imaging; 2024 Sep 11. PubMed ID: 39259226
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.